TITLE

COMMENTARY: Review: On-demand maintenance therapy with proton pump inhibitors is as effective as continuous therapy for nonerosive GERD

AUTHOR(S)
Mummadi, Rajasekhara R.; Pasricha, Pankaj J.
PUB. DATE
November 2007
SOURCE
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p69
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects upon the findings of a study showing the on-demand maintenance therapy to be more effective than the placebo, in the treatment of patients with gastroesophageal reflux disease (GERD). He supports the heterogeneous nature of the study and considers the evasion of meta-analysis, appropriate for the study's results. He suggests the implications of the results on the pharmaceutical industry. He also comments on the controversy over the categorical or spectrum nature of the GERD.
ACCESSION #
28019877

 

Related Articles

  • Review: On-demand maintenance therapy with proton pump inhibitors is as effective as continuous therapy for nonerosive GERD.  // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p69 

    The article focuses on a clinical study analyzing the effectiveness of on-demand maintenance therapy with proton pump inhibitors (PPIs) in treating patients with gastroesophageal reflux disease (GERD). It discusses the methods followed, data sources, patients' selection criteria and the...

  • H2 Antagonists in the Treatment of Reflux Esophagitis: A Critical Analysis. Stalnikowicz-Darvasi, Ruth // American Journal of Gastroenterology;Mar1989, Vol. 84 Issue 3, p245 

    To ascertain through clinical and endoscopic assessment, the clinical benefits of using H2 antagonists to treat patients with reflux esophagitis, we researched the English language literature using Index Medicus (1978-87) and bibliographic resources of textbooks. We selected 10 of 20...

  • PRODUCT NEWS.  // Medical Marketing & Media;May2001, Vol. 36 Issue 5, p28 

    Reports on the approval of the U.S. Food and Drug Administration to American Home Products Corp.'s Protonix I.V. intravaneous formulation for short-term treatment of gastroesophageal reflux disease.

  • Buzz'N BYTES.  // Drug Store News;12/16/2013, Vol. 35 Issue 12, p88 

    The article offers information related to pharmaceutical industry in the U.S. including the approval of the drugs for gastroesophageal reflex disease (GERD) treatment, the launch of the topical drug for actinic keratosis treatment, and the approval of the testosterone topical solution.

  • Omeprazole maintenance therapy for GERD. Parks, Susan Mockus // Journal of Family Practice;Oct97, Vol. 45 Issue 4, p292 

    The article discusses research being done on the effectiveness of omeprazole maintenance therapy on gastroesophageal reflux disease (GERD). It references a study by T. L. Venables, R. D. Newland, A. C. Patel, J. Hole, M. B. Copeman and M. L. Turbitt published in the 1997 issue of "Scandinavian...

  • A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. Ohara, Shuichi; Haruma, Ken; Kinoshita, Yoshikazu; Kusano, Motoyasu // Journal of Gastroenterology;Dec2010, Vol. 45 Issue 12, p1219 

    Purpose: This randomized, double-blind, controlled study examined whether lafutidine is superior to placebo and non-inferior to famotidine in terms of healing rates as assessed by endoscopy in Japanese patients with mild reflux esophagitis. Safety and improvement in symptoms of heartburn were...

  • Xenoport's GERD Phase IIb Data Give Investors Heartburn. Shaffer, Catherine // BioWorld Today;3/22/2011, Vol. 22 Issue 55, p1 

    The article discusses the performance of Xenoport Inc.'s arbaclofen placarbil, the company's indication for gastroesophageal reflux (GERD), versus placebo in a Phase llb trial. Subjects with GERD symptoms were observed while being treated with proton pump inhibitor (PPI). The study showed...

  • Items of Interest. Rollins, Judy A. // Pediatric Nursing;Mar/Apr2007, Vol. 33 Issue 2, p183 

    The article focuses on the safety and efficacy of AXID Oral Solution (OS) for treating infants suffering from gastroesophageal reflux disease (GERD). This Phase III clinical trial was sponsored by the Braintree Laboratories. It aims to evaluate the efficacy, acceptability and safety of AXID OS...

  • A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Boeckxstaens, Guy E.; Beaumont, Hanneke; Hatlebakk, Jan G.; Silberg, Debra G.; Bj√∂rck, Karin; Karlsson, Maria; Denison, Hans // Gut;Sep2011, Vol. 60 Issue 9, p1182 

    Objective To evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastrooesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy. Methods A double-blind, placebo-controlled,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics